2021 journal article

Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs

CLINICAL CANCER RESEARCH, 27(11), 3005–3016.

By: A. LeBlanc*, C. Mazcko*, A. Cherukuri*, E. Berger*, W. Kisseberth*, M. Brown*, S. Lana*, K. Weishaar* ...

MeSH headings : Amputation, Surgical; Animals; Bone Neoplasms / genetics; Bone Neoplasms / mortality; Bone Neoplasms / therapy; Bone Neoplasms / veterinary; Carboplatin / administration & dosage; Chemotherapy, Adjuvant; Combined Modality Therapy / veterinary; Dog Diseases / mortality; Dog Diseases / therapy; Dogs; Osteosarcoma / genetics; Osteosarcoma / mortality; Osteosarcoma / therapy; Osteosarcoma / veterinary; Pets; Prospective Studies; Signal Transduction / drug effects; Sirolimus / administration & dosage; Sirolimus / pharmacology; Survival Rate; TOR Serine-Threonine Kinases / metabolism; Treatment Outcome
TL;DR: In a population of pet dogs nongenomically segmented for predicted mTOR inhibition response, sequentially administered adjuvant sirolimus, although well tolerated when added to a backbone of therapy, did not extend DFI or survival in dogs with appendicular osteosarcoma. (via Semantic Scholar)
Source: Web Of Science
Added: June 21, 2021